GlaxoSmithKline plc (GSK)

Last Closing Price: 43.75 (2022-07-01)

Company Description

Glaxo has 3 core businesses - Pharmaceuticals, Vaccines and Consumer Healthcare. The company has made significant progress in expanding its presence in emerging markets by acquiring product portfolios from companies like Bristol-Myers and UCB. In August 2019, Glaxo and Pfizer merged their consumer healthcare unit into a new JV. Glaxo owns a controlling stake in the JV. Glaxo plans to split itself into two standalone companies. The new Glaxo will be a biopharma company. Glaxo intends to separate its Consumer Healthcare segment into a standalone company in 2022. The independent Consumer Healthcare company will be named Haleon. In 2015, Glaxo divested two quadrivalent meningitis ACWY vaccines ' Nimenrix and Mencevax ' to Pfizer, a portfolio of OTC brands to Perrigo, and all its remaining rights to Arzerra for auto-immune indications including multiple sclerosis to Novartis. In January 2019, Glaxo acquired Tesaro, an oncology focused biotech company, which added the PARP inhibitor Zejula to its portfolio.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $46.91B
Net Income (Most Recent Fiscal Year) $6.03B
PE Ratio (Current Year Earnings Estimate) 13.84
PE Ratio (Trailing 12 Months) 12.98
PEG Ratio (Long Term Growth Estimate) 1.96
Price to Sales Ratio (Trailing 12 Months) 2.23
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 3.66
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) 15.12
Pre-Tax Margin (Trailing 12 Months) 17.83%
Net Margin (Trailing 12 Months) 14.03%
Return on Equity (Trailing 12 Months) 28.13%
Return on Assets (Trailing 12 Months) 7.57%
Current Ratio (Most Recent Fiscal Quarter) 1.19
Quick Ratio (Most Recent Fiscal Quarter) 0.95
Debt to Common Equity (Most Recent Fiscal Quarter) 1.29
Inventory Turnover (Trailing 12 Months) 2.09
Book Value per Share (Most Recent Fiscal Quarter) $10.90
Earnings per Share (Most Recent Fiscal Quarter) $0.88
Earnings per Share (Most Recent Fiscal Year) $3.11
Diluted Earnings per Share (Trailing 12 Months) $2.77
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers - General
Common Shares Outstanding 2.54B
Free Float 2.29B
Market Capitalization $111.20B
Average Volume (Last 20 Days) 5.87M
Beta (Past 60 Months) 0.61
Percentage Held By Insiders (Latest Annual Proxy Report) 10.00%
Percentage Held By Institutions (Latest 13F Reports) 32.76%
Annual Dividend (Based on Last Quarter) $1.34
Dividend Yield (Based on Last Quarter) 3.05%